Find a Physician | How to Contribute | About Us | Clinical Trials
 
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

All: Soft Tissue

A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

The purpose of this study is to evaluate the efficacy either single agent olaparib or the combination of cediranib and olaparib, as measured by PFS, as compared to standard platinum-based chemotherapy in the setting of recurrent platinum sensitive ovarian, primary peritoneal or fallopian tube cancer.

Status: Accepting New Patients
Principal Investigator: Shohreh Shahabi

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

A Phase 1 Study Of COTI-2 For The Treatment Of Advanced Or Recurrent Gynecologic Malignancies

The main purpose of this study is to learn about and compare the highest tolerable doses of the drug COTI-2 that can be given to patients with advanced or recurrent endometrial, ovarian, primary peritoneal, or fallopian tube cancer.

Status: Accepting New Patients
Principal Investigator: Wilberto Nieves-Neira

A Phase II Study of Pazopanib as Front-Line Therapy in Patients with Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy

The purpose of this clinical research study is to learn if pazopanib is useful in treating people with soft tissue sarcoma as their first treatment.

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This purpose of this study is to determine the safety and effectiveness of a drug called tazemetostat to treat cancer

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

The purpose of this study is to determine if a change in diet and exercise in women with ovarian, fallopian tube, or primary peritoneal cancer, has an effect on the length of time patients are cancer-free following initial treatment.

Status: Accepting New Patients
Principal Investigator: Shohreh Shahabi

A Phase II Study of Pazopanib with Oral Topotecan in Patients with Metastatic and Non-resectable Soft Tissue and Bone Sarcomas

The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied.

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

A Blanket Protocol to Study Oral Regorafenib in Patients with Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing–Like Sarcomas

The purpose of this study is to compare the safety (side effects) and effectiveness of giving participants the study drug regorafenib versus a placebo (sugar pill).

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma.

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

The goal of this study is to find out what effects (good and/or bad) pazopanib given with both chemotherapy and radiation therapy has on people with intermediate and high risk non-Rhabdomyosarcoma soft tissue sarcomas (NRSTS).

Status: Accepting New Patients
Principal Investigator: David Walterhouse

A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma

The purpose of this study is twofold. The first purpose is to evaluate if the addition of vincristine/topotecan/cyclophosphamide (VTC) to standard chemotherapy can improve the treatment of Ewing sarcoma. The second purpose is to find out if PET scans could be useful in evaluating the beneficial effects of the treatment.

Status: Accepting New Patients
Principal Investigator: David Walterhouse

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

last updated: Sat - June 24, 2017 - 02:50 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.